Researchers Database

murata kazumoto

    InfectionandImmunityVirology Professor
Contact: kmuratajichi.ac.jp
Last Updated :2021/12/04

Researcher Information

J-Global ID

Research Areas

  • Life sciences / Virology

Academic & Professional Experience

  • 2020/04 - Today  Jichi Medical UniversityDivision of Virology, Department of Infection and ImmunityProfessor

Education

  •        - 1988  Jichi Medical University  Faculty of Medicine

Association Memberships

  • American Association for the Study of Liver Diseases   日本消化器内視鏡学会   日本内科学会   日本消化器病学会   日本肝臓学会   

Published Papers

  • Masaharu Takahashi, Tsutomu Nishizawa, Yukihiro Sato, Shinichi Miyazaki, Tatsuya Aikawa, Kozo Ashida, Tomoko Tamaru, Kunihiko Oguro, Fumihiro Hayakawa, Hiroyuki Matsuoka, Hideaki Ozaki, Yuuji Kodera, Masahiko Irokawa, Hideo Hirose, Shigeo Nagashima, Manri Kawakami, Hitoshi Mizuo, Hiroaki Okamoto, Kazumoto Murata
    Virus Research 287 198106 - 198106 0168-1702 2020/10 [Refereed]
  • Akihiro Matsumoto, Shuhei Nishiguchi, Hirayuki Enomoto, Yasuhito Tanaka, Noboru Shinkai, Chiaki Okuse, Jong-Hon Kang, Takeshi Matsui, Shiho Miyase, Hiroshi Yatsuhashi, Shinya Nagaoka, Tatsuo Kanda, Masaru Enomoto, Ryoko Yamada, Naoki Hiramatsu, Satoru Saito, Koichi Takaguchi, Kiyoaki Ito, Tsutomu Masaki, Daisuke Morihara, Masataka Tsuge, Kazuaki Chayama, Fusao Ikeda, Tatehiro Kagawa, Yasuteru Kondo, Kazumoto Murata, Eiji Tanaka
    Journal of Gastroenterology 55 (10) 977 - 989 0944-1174 2020/10 [Refereed]
     
    BACKGROUND: A prospective pilot study of tenofovir disoproxil fumarate (TDF) and pegylated interferon alpha 2a (P-IFN) add-on therapy was conducted to evaluate its efficacy in reducing viral antigen levels in Japanese patients with chronic hepatitis B (UMIN 000020179). METHODS: Patients with chronic hepatitis B receiving maintenance TDF therapy and exhibiting hepatitis B surface antigen (HBsAg) level > 800 IU/ml were divided into two arms. P-IFN was added for 48 weeks in the add-on arm (n = 32), while TDF monotherapy was maintained in the control arm (n = 51). Both groups were followed for 96 weeks after baseline measurements. RESULTS: Almost all patients in the control arm displayed a slow and constant reduction in HBsAg during follow-up. In contrast, roughly half of the add-on arm exhibited a sharp decline in HBsAg during P-IFN administration, which disappeared after halting P-IFN. At 96 weeks after baseline, 41% (13/32) of patients in the add-on arm had shown a rapid decrease in HBsAg, versus 2% (1/51) in the control arm (p < 0.001). Add-on therapy and increased cytotoxic T-cell response were significant factors associated with a rapid decrease in HBsAg according to multivariate analysis. In addition, higher HB core-related antigen (HBcrAg) level at baseline (p = 0.001) and add-on therapy (p = 0.036) were significant factors associated with a rapid reduction in HBcrAg. CONCLUSIONS: TDF and P-IFN add-on therapy in Japanese patients with chronic hepatitis B facilitated rapid decreases in HBsAg and HBcrAg. Further studies are needed to improve early HBsAg clearance rate.
  • Kazumoto Murata, Senko Tsukuda, Futoshi Suizu, Akihiro Kimura, Masaya Sugiyama, Koichi Watashi, Masayuki Noguchi, Masashi Mizokami
    Hepatology 71 (5) 1533 - 1545 0270-9139 2020/05 [Refereed]
     
    BACKGROUND AND AIMS: Current treatment with nucleos(t)ide analogs (NUCs) safely controls the replication of hepatitis B virus (HBV) and improves prognosis in patients with HBV. However, the inability to completely clear HBV is problematic, and novel therapies are desired. It has been believed that all NUCs have similar functions to inhibit HBV reverse transcriptase. However, our recent findings that only acyclic nucleoside phosphonates (ANPs; adefovir dipivoxil and tenofovir disoproxil fumarate) had an additional effect of inducing interferon (IFN)-λ3 in the gastrointestinal tract suggests that ANPs are not only distinct from nucleoside analogs (lamivudine and entecavir) in their structures but also in their functions. Because enteric lipopolysaccharide (LPS) can cross the intestine and affect peripheral blood mononuclear cells (PBMCs), we hypothesized that orally administered ANPs could have further additional effects to modulate LPS-mediated cytokine profile in PBMCs. APPROACH AND RESULTS: This study showed that pretreatment of PBMCs, from either healthy volunteers or patients with HBV, with ANPs inhibited LPS-mediated interleukin (IL)-10 production, which reciprocally induced IL-12p70 and tumor necrosis factor-α production in a dose-dependent manner. Furthermore, the combination of IFN-α and ANPs synergistically enhanced LPS-mediated IL-12p70 production in PBMCs. Mechanistic analyses revealed that cellular metabolites of ANPs directly bound the Akt protein, inhibiting its translocation to the plasma membrane, thereby impairing Akt phosphorylation. Therefore, pretreatment of PBMCs with ANPs impairs LPS-mediated IL-10 production. CONCLUSIONS: Among NUCs, only ANPs have an additional pharmacological effect modulating LPS-mediated cytokine production, which is expected to produce favorable immune responses toward HBV elimination. This additional immunomodulation by ANPs in PBMCs, as well as IFN-λ3 induction in the gastrointestinal tract, provides insights into HBV treatment.
  • Norie Yamada, Asako Murayama, Masaaki Shiina, Hussein Hassan Aly, Masashi Iwamoto, Senko Tsukuda, Koichi Watashi, Tomohisa Tanaka, Kohji Moriishi, Hironori Nishitsuji, Masaya Sugiyama, Masashi Mizokami, Kunitada Shimotohno, Masamichi Muramatsu, Kazumoto Murata, Takanobu Kato
    Hepatology Research 50 (3) 283 - 291 1386-6346 2020/03 [Refereed]
     
    AIM: Interferon (IFN)-λ3 is known to have antiviral effects against various pathogens. Recently, it has been reported that the production of IFN-λ3 in colon cells after the administration of nucleotide analogs is expected to reduce hepatitis B surface antigen in chronic hepatitis B patients. Here, we aimed to prove the antiviral effects of IFN-λ3 on hepatitis B virus (HBV) by using an in vitro HBV production and infection system. METHODS: We used HepG2.2.15-derived HBV as an inoculum and the replication-competent molecular clone of HBV as a replication model. RESULTS: By administering IFN-λ3 to HepG2 cells transfected with the HBV molecular clone, the production of hepatitis B surface antigen and hepatitis B core-related antigen was reduced dose-dependently. IFN-λ3 treatment also reduced the number of HBV-positive cells and the synthesis of covalently closed circular DNA after infection of HepG2.2.15-derived HBV to sodium taurocholate cotransporting polypeptide-transduced HepG2 cells. The inhibitory effect on HBV infection by IFN-λ3 was confirmed by using a recombinant a HBV reporter virus system. To elucidate the underlying mechanisms of the anti-HBV effect of IFN-λ3, we assessed the transcription of HBV RNA and the production of core-associated HBV DNA in HBV molecular clone-transfected HepG2 cells, and found that both parameters were reduced by IFN-λ3. CONCLUSIONS: We observed that the administration of IFN-λ3 inhibits HBV infection and the production of HBV proteins at the HBV RNA transcription level. This finding provides novel insight into the treatment of chronic hepatitis B patients with the administration or induction of IFN-λ3.
  • Kazumoto Murata, Jong-Hon Kang, Shigeo Nagashima, Takeshi Matsui, Yoshiyasu Karino, Yoshiya Yamamoto, Tomofumi Atarashi, Masatsugu Oohara, Minoru Uebayashi, Hidekatsu Sakata, Keiji Matsubayashi, Kazuaki Takahashi, Masahiro Arai, Shunji Mishiro, Masaya Sugiyama, Masashi Mizokami, Hiroaki Okamoto
    Cytokine 125 154816 - 154816 1043-4666 2020/01 [Refereed]
  • Yuki Hitomi, Kazuko Ueno, Yosuke Kawai, Nao Nishida, Kaname Kojima, Minae Kawashima, Yoshihiro Aiba, Hitomi Nakamura, Hiroshi Kouno, Hirotaka Kouno, Hajime Ohta, Kazuhiro Sugi, Toshiki Nikami, Tsutomu Yamashita, Shinji Katsushima, Toshiki Komeda, Keisuke Ario, Atsushi Naganuma, Masaaki Shimada, Noboru Hirashima, Kaname Yoshizawa, Fujio Makita, Kiyoshi Furuta, Masahiro Kikuchi, Noriaki Naeshiro, Hironao Takahashi, Yutaka Mano, Haruhiro Yamashita, Kouki Matsushita, Seiji Tsunematsu, Iwao Yabuuchi, Hideo Nishimura, Yusuke Shimada, Kazuhiko Yamauchi, Tatsuji Komatsu, Rie Sugimoto, Hironori Sakai, Eiji Mita, Masaharu Koda, Yoko Nakamura, Hiroshi Kamitsukasa, Takeaki Sato, Makoto Nakamuta, Naohiko Masaki, Hajime Takikawa, Atsushi Tanaka, Hiromasa Ohira, Mikio Zeniya, Masanori Abe, Shuichi Kaneko, Masao Honda, Kuniaki Arai, Teruko Arinaga-Hino, Etsuko Hashimoto, Makiko Taniai, Takeji Umemura, Satoru Joshita, Kazuhiko Nakao, Tatsuki Ichikawa, Hidetaka Shibata, Akinobu Takaki, Satoshi Yamagiwa, Masataka Seike, Shotaro Sakisaka, Yasuaki Takeyama, Masaru Harada, Michio Senju, Osamu Yokosuka, Tatsuo Kanda, Yoshiyuki Ueno, Hirotoshi Ebinuma, Takashi Himoto, Kazumoto Murata, Shinji Shimoda, Shinya Nagaoka, Seigo Abiru, Atsumasa Komori, Kiyoshi Migita, Masahiro Ito, Hiroshi Yatsuhashi, Yoshihiko Maehara, Shinji Uemoto, Norihiro Kokudo, Masao Nagasaki, Katsushi Tokunaga, Minoru Nakamura
    Scientific Reports 9 (1) 2019/12 [Refereed]
  • Nucleotide analogueによるIFN-lambda3誘導
    村田一素
    肝胆膵 78 (6) 955 - 961 2019/06 [Invited]
  • Emi Inoue‐Shinomiya, Miyako Murakawa, Yasuhiro Asahina, Mina Nakagawa, Jun Tsuchiya, Ayako Sato, Tomoyuki Tsunoda, Masato Miyoshi, Sayuri Nitta, Fukiko Kawai‐Kitahata, Yasuhiro Itsui, Seishin Azuma, Sei Kakinuma, Kazumoto Murata, Masashi Mizokami, Mamoru Watanabe
    Hepatology Research 49 (5) 500 - 511 1386-6346 2019/05 [Refereed]
  • B型肝炎の抗ウイルス療法:肝発癌の制御を目指した治療の最前線 Acyclic nucleoside phosphonatesによる免疫賦活および抗腫瘍効果
    村田 一素, 杉山 真也, 溝上 雅史
    肝臓 (一社)日本肝臓学会 60 (Suppl.1) A73 - A73 0451-4203 2019/04
  • 病初期HEV感染におけるIFN-lambda3の臨床的意義
    姜 貞憲, 村田 一素, 松居 剛志, 狩野 吉康, 山本 義也, 新 智文, 大原 正嗣, 上林 実, 高橋 和明, 新井 雅裕, 三代 俊治, 杉山 真也, 溝上 雅史, 岡本 宏明
    肝臓 (一社)日本肝臓学会 60 (Suppl.1) A465 - A465 0451-4203 2019/04
  • 村田 一素, 杉山 真也, 溝上 雅史
    日本消化器病学会雑誌 (一財)日本消化器病学会 116 (臨増総会) A199 - A199 0446-6586 2019/03
  • Nao Nishida, Masaya Sugiyama, Hiromi Sawai, Sohji Nishina, Aiko Sakai, Jun Ohashi, Seik-Soon Khor, Keisuke Kakisaka, Takayo Tsuchiura, Keisuke Hino, Ryo Sumazaki, Yasuhiro Takikawa, Kazumoto Murata, Tatsuo Kanda, Osamu Yokosuka, Katsushi Tokunaga, Masashi Mizokami
    Hepatology 68 (3) 848 - 858 0270-9139 2018/09 [Refereed]
  • 須藤大輔, 村田一素, 大竹孝明, 一石英一郎, 佐藤貴一, 高橋芳久, 岡田真也, 福富 京, 高後 裕
    肝臓 (一社)日本肝臓学会 59 (6) 277 - 283 0451-4203 2018/06 [Refereed]
     
    症例は生来健康な48歳女性。倦怠感、嘔気を主訴に近医を受診し、血液検査にて肝障害を指摘されて紹介受診した。入院時血液検査では、AST 868IU/L、ALT 1,205IU/L、Alp 479IU/L、γ-GTP 254IU/Lと肝細胞障害型の肝胆道系酵素異常を認めた。飲酒歴・薬剤内服歴なく、かつ各種肝炎ウイルスマーカーは陰性であった。自己免疫性肝炎(AIH)の急性発症を疑い、肝生検を施行したところ、門脈域を中心としたIgG4陽性形質細胞の浸潤を認め、かつ血清IgG4値が669mg/dLと高値を示した。明らかな胆管への細胞浸潤は認めなかった。以上より、IgG4関連AIH(IgG4-AIH)と診断し、プレドニゾロン30mg/日を投与したところ、肝障害は速やかに改善した。IgG4-AIHの報告は少なく、その臨床病理学的特徴は解明されていない。今後の詳細な解析が期待される。(著者抄録)
  • B型肝炎新規治療薬の探索の現状 新規治療薬探索のためのアデフォビル・テノフォビルによるIFN-λ3誘導機序の解明
    村田 一素, 杉山 真也, 溝上 雅史
    肝臓 (一社)日本肝臓学会 59 (Suppl.1) A205 - A205 0451-4203 2018/04
  • Kazumoto Murata, Akiko Saito, Satoshi Katagiri, Shunichi Ariizumi, Masayuki Nakano, Masakazu Yamamoto
    Journal of Medical Ultrasonics 45 (2) 223 - 229 1346-4523 2018/04 [Refereed]
  • Kazumoto Murata, Mai Asano, Akihiro Matsumoto, Masaya Sugiyama, Nao Nishida, Eiji Tanaka, Taisuke Inoue, Minoru Sakamoto, Nobuyuki Enomoto, Takayoshi Shirasaki, Masao Honda, Shuichi Kaneko, Hiroyuki Gatanaga, Shinichi Oka, Yuki I Kawamura, Taeko Dohi, Yasutaka Shuno, Hideaki Yano, Masashi Mizokami
    Gut 67 (2) 362 - 371 0017-5749 2018/02 [Refereed]
     
    ObjectiveThe clinical significance of polymorphisms in the interleukin-28B gene encoding interferon (IFN)-λ3, which has antiviral effects, is known in chronic HCV but not in HBV infection. Thus, we measured IFN-λ3 levels in patients with HBV and investigated its clinical significance and association with nucleos(t)ide (NUC) analogue administration. DesignSerum IFN-λ3 level was measured in 254 patients with HBV with varying clinical conditions using our own high sensitivity method. The resulting values were compared with various clinical variables. In addition, cell lines originating from various organs were cultured with NUCs, and the production of IFN-λ3 was evaluated. ResultsHigher serum IFN-λ3 levels were detected in the patients treated with nucleotide analogues (adefovir or tenofovir) compared with those treated with nucleoside analogues (lamivudine or entecavir). There were no other differences in the clinical background between the two groups. A rise in the serum IFN-λ3 levels was observed during additional administration of the nucleotide analogues. In vitro experiments showed that the nucleotide analogues directly and dose-dependently induced IFN-λ3 production only in colon cancer cells. Furthermore, the supernatant from cultured adefovir-treated colon cancer cells significantly induced IFN-stimulated genes (ISGs) and inhibited hepatitis B surface antigen (HBsAg) production in hepatoma cells, as compared with the supernatant from entecavir-treated cells. ConclusionsWe discovered that the nucleotide analogues show an additional pharmacological effect by inducing IFN-λ3 production, which further induces ISGs and results in a reduction of HBsAg production. These findings provide novel insights for HBV treatment and suggest IFN-λ3 induction as a possible target.
  • Akihiro Matsumoto, Shuhei Nishiguchi, Hirayuki Enomoto, Jong-Hon Kang, Yasuhito Tanaka, Noboru Shinkai, Masayuki Kurosaki, Masaru Enomoto, Tatsuo Kanda, Osamu Yokosuka, Hiroshi Yatsuhashi, Shinya Nagaoka, Chiaki Okuse, Tatehiro Kagawa, Tetsuya Mine, Koichi Takaguchi, Satoru Saito, Keisuke Hino, Fusao Ikeda, Shotaro Sakisaka, Daisuke Morihara, Shiho Miyase, Masataka Tsuge, Kazuaki Chayama, Naoki Hiramatsu, Yoshiyuki Suzuki, Kazumoto Murata, Eiji Tanaka
    Journal of Gastroenterology 53 (2) 247 - 257 0944-1174 2018/02 [Refereed]
     
    This prospective cohort study searched for factors associated with a response to nucleos(t)ide analogue/peg-interferon (NUC/peg-IFN) sequential therapy.A total of 95 patients with chronic hepatitis B being treated with NUCs were enrolled. Immediately following NUC cessation, peg-IFN was administered at 180 A mu g/dose weekly for 48 weeks.Twenty-six patients (27%) were judged to be responders at 48 weeks after the completion of peg-IFN. Analysis of baseline factors revealed that hepatitis B surface antigen (HBsAg) < 3.1 log IU/ml and HB core-related antigen (HBcrAg) < 3.9 log U/ml were significant indicators of a treatment response. The levels of the markers decreased in both responders and non-responders during peg-IFN therapy but continued falling in responders only after halting peg-IFN. Lower HBsAg (< 2.0 log IU/ml) and HBcrAg (< 3.8 log U/ml) levels at the time of response judgment were also significantly associated with a favorable response. While lower HBcrAg at baseline was the sole predictor of decreased HBcrAg levels at judgment, lower HBsAg, lower HBcrAg, and the use of adefovir dipivoxil at baseline predicted decreased HBsAg levels at the study endpoint. The use of adefovir dipivoxil was also associated with higher serum IFN-lambda 3, which might have contributed to the reduction in patient HBsAg levels.The combinational use of HBsAg and HBcrAg levels at baseline and their changes throughout sequential therapy may be useful for predicting a response to NUC/peg-IFN sequential therapy.
  • 核酸アナログ製剤によるIFN-lambda3誘導とそれを標的としたB型肝炎治療薬の探索
    村田一素, 前仲勝実, 溝上雅史
    Mebio 1 80 - 87 2018/01 [Invited]
  • アデフォビル、テノフォビルによるIFN-lambda3誘導とその意義
    村田一素, 杉山真也
    医学のあゆみ 262 1327 - 1330 2017/09 [Invited]
  • Mikio Yanase, Kazumoto Murata, Shintaro Mikami, Yuichi Nozaki, Naohiko Masaki, Masashi Mizokami
    Hepatology Research 46 (13) 1330 - 1337 1386-6346 2016/12 [Refereed]
  • Yoko Yamagiwa, Mai Asano, Youhei Kawasaki, Masaaki Korenaga, Kazumoto Murata, Tatsuya Kanto, Masashi Mizokami, Naohiko Masaki
    Cytokine 88 29 - 36 1043-4666 2016/12 [Refereed]
  • エジプト人におけるIL28B遺伝子プロモーター領域のチミン-アデニンの二塩基反復配列とC型肝炎ウイルス自然排除の相関
    平峯 智, 古庄 憲浩, 加勢田 富士子, 高山 耕治, 浦 和也, 志水 元洋, 豊田 一弘, 小川 栄一, 村田 昌之, 溝上 雅史, 林 純, 杉山 真也, 是永 匡紹, 村田 一素, 正木 尚彦
    感染症学雑誌 (一社)日本感染症学会 90 (臨増) 260 - 260 0387-5911 2016/03
  • Kiyoaki Ito, Hiroshi Yotsuyanagi, Masaya Sugiyama, Hiroshi Yatsuhashi, Yoshiyasu Karino, Yasuhiro Takikawa, Takafumi Saito, Yasuji Arase, Fumio Imazeki, Masayuki Kurosaki, Takeji Umemura, Takafumi Ichida, Hidenori Toyoda, Masashi Yoneda, Yasuhito Tanaka, Eiji Mita, Kazuhide Yamamoto, Kojiro Michitaka, Tatsuji Maeshiro, Junko Tanuma, Masaaki Korenaga, Kazumoto Murata, Naohiko Masaki, Kazuhiko Koike, Masashi Mizokami
    Journal of Gastroenterology and Hepatology 31 (1) 180 - 189 0815-9319 2016/01 [Refereed]
  • .核酸アナログ製剤の投与により肝予備能が著明に改善した非代償性B型肝硬変例
    村田一素, 正木尚彦
    30 1469 - 1474 2015/12 [Invited]
  • Naohiko Masaki, Yoko Yamagiwa, Takuro Shimbo, Kazumoto Murata, Masaaki Korenaga, Tatsuya Kanto, Masashi Mizokami
    BMC Public Health 15 (1) 2015/12 [Refereed]
  • Satoshi Hiramine, Masaya Sugiyama, Norihiro Furusyo, Hirofumi Uto, Akio Ido, Hirohito Tsubouchi, Hisayoshi Watanabe, Yoshiyuki Ueno, Masaaki Korenaga, Kazumoto Murata, Naohiko Masaki, Jun Hayashi, David L. Thomas, Masashi Mizokami
    Journal of Gastroenterology 50 (10) 1069 - 1077 0944-1174 2015/10 [Refereed]
  • HCV薬剤耐性変異株測定の問題点
    是永 匡紹, 渡部 武, 上山 三鈴, 熊谷 恵理奈, 杉山 真也, 由雄 祥代, 青木 孝彦, 山極 洋子, 是永 圭子, 今村 雅俊, 村田 一素, 考藤 達哉, 正木 尚彦, 溝上 雅史
    肝臓 (一社)日本肝臓学会 56 (Suppl.2) A712 - A712 0451-4203 2015/09
  • Yoshihiko Aoki, Masaya Sugiyama, Kazumoto Murata, Sachiyo Yoshio, Masayuki Kurosaki, Satoru Hashimoto, Hiroshi Yatsuhashi, Hideyuki Nomura, Jong-Hon Kang, Tsutomu Takeda, Shigeko Naito, Tatsuji Kimura, Yoko Yamagiwa, Masaaki Korenaga, Masatoshi Imamura, Naohiko Masaki, Namiki Izumi, Masayoshi Kage, Masashi Mizokami, Tatsuya Kanto
    Journal of Gastroenterology 50 (8) 894 - 902 0944-1174 2015/08 [Refereed]
  • 肝特異的蛋白量低下の原因精査を行った高齢男性
    村田一素, 正木尚彦
    臨床消化器内科 30 722 - 726 2015/07 [Invited]
  • C型慢性肝炎患者における血清IFNλ3測定とその臨床的意義についての検討
    青木 孝彦, 杉山 真也, 村田 一素, 由雄 祥代, 八橋 弘, 野村 秀幸, 姜 貞憲, 竹田 努, 山極 洋子, 是永 匡紹, 今村 雅俊, 正木 尚彦, 泉 並木, 鹿毛 政義, 溝上 雅史, 考藤 達哉
    肝臓 (一社)日本肝臓学会 56 (Suppl.1) A320 - A320 0451-4203 2015/04
  • C型慢性肝炎ウイルス排除例に出現した高熱を伴う肝胆道系酵素異常
    村田一素, 正木尚彦
    臨床消化器内科 30 381 - 385 2015/03 [Invited]
  • B型肝炎ウイルスワクチンの現状とその対策―抗体が陽性にならない私、どうすればよいのか?-.
    村田一素
    肝臓クリニカルアップデー 1 183 - 187 2015/02 [Invited]
  • HBVキャリアへの薬物治療中止時期の見きわめ
    村田一素, 溝上雅史
    日本医事新報 47 61 - 63 2015/01 [Invited]
  • Naohiko Masaki, Masaya Sugiyama, Noritomo Shimada, Yasuhito Tanaka, Makoto Nakamuta, Namiki Izumi, Sumio Watanabe, Akihito Tsubota, Masafumi Komatsu, Tsutomu Masaki, Nobuyuki Enomoto, Masashi Yoneda, Kazumoto Murata, Kiyoaki Ito, Kazuhiko Koike, Masashi Mizokami
    Journal of Gastroenterology and Hepatology 29 (12) 1996 - 2005 0815-9319 2014/12 [Refereed]
  • Motokazu Mukaide, Masaya Sugiyama, Masaaki Korenaga, Kazumoto Murata, Tatsuya Kanto, Naohiko Masaki, Masashi Mizokami
    Journal of Virological Methods 207 169 - 177 0166-0934 2014/10 [Refereed]
  • NK細胞と樹状細胞の相互作用によるHBV複製抑制効果
    由雄 祥代, 考藤 達哉, 杉山 真也, 青木 孝彦, 西田 奈央, 是永 匡紹, 村田 一素, 溝上 雅史
    肝臓 (一社)日本肝臓学会 55 (Suppl.2) A586 - A586 0451-4203 2014/09
  • 超高感度デジタルPCR法を用いたHCVコア70変異定量法
    向出 雅一, 杉山 真也, 是永 匡紹, 村田 一素, 考藤 達哉, 正木 尚彦, 溝上 雅史
    肝臓 (一社)日本肝臓学会 55 (Suppl.2) A649 - A649 0451-4203 2014/09
  • 高齢・非線維化進展C型慢性肝疾患をcontrolとした遺伝子多型測定と発癌予測
    是永 匡紹, 杉山 真也, 西田 奈央, 青木 孝彦, 由雄 祥代, 山極 洋子, 是永 圭子, 今村 雅俊, 村田 一素, 考藤 達哉, 正木 尚彦, 溝上 雅史
    肝臓 (一社)日本肝臓学会 55 (Suppl.2) A654 - A654 0451-4203 2014/09
  • C型肝炎ウイルス自然排除とインターロイキン28B遺伝子プロモーター領域のTA repeatの関連の検討
    平峯 智, 古庄 憲浩, 光本 富士子, 高山 耕治, 浦 和也, 志水 元洋, 豊田 一弘, 小川 栄一, 貝沼 茂三郎, 村田 昌之, 溝上 雅史, 林 純, 杉山 真也, 是永 匡紹, 村田 一素, 正木 尚彦
    日本化学療法学会雑誌 (公社)日本化学療法学会 62 (Suppl.A) 336 - 336 1340-7007 2014/05
  • ペグインターフェロン/リバビリン/テラプレビル3剤併用療法における血清IP-10値による治療効果予測の検討
    山極 洋子, 正木 尚彦, 村田 一素, 西田 奈央, 杉山 真也, 考藤 達哉, 是永 匡紹, 今村 雅俊, 青木 孝彦, 竹田 努, 国際医療研究開発費24指101協力施設
    肝臓 (一社)日本肝臓学会 55 (Suppl.1) A219 - A219 0451-4203 2014/04
  • HBV複製抑制機構におけるインターフェロン(IFN-α/γ/λ)の役割-樹状細胞とNK細胞のクロストーク
    由雄 祥代, 考藤 達哉, 杉山 真也, 是永 匡紹, 村田 一素, 溝上 雅史
    肝臓 (一社)日本肝臓学会 55 (Suppl.1) A260 - A260 0451-4203 2014/04
  • 肝内脂肪蓄積に関与する脾臓内鉄濃度と肝ミトコンドリア呼吸鎖複合体IV障害
    是永 匡紹, 杉山 真也, 辻 美保子, 近藤 美幸, 由雄 祥代, 是永 圭子, 村田 一素, 考藤 達哉, 西田 奈央, 正木 尚彦, 溝上 雅史
    肝臓 (一社)日本肝臓学会 55 (Suppl.1) A319 - A319 0451-4203 2014/04
  • 糖尿病関連SNPsとPNPLA3を用いた糖尿病合併肝病態促進症例の囲い込み
    是永 匡紹, 西田 奈央, 是永 圭子, 竹田 努, 青木 孝彦, 由雄 祥代, 山極 洋子, 杉山 真也, 今村 雅俊, 柳内 秀勝, 山田 慎吾, 川口 巧, 佐田 通夫, 村田 一素, 考藤 達哉, 正木 尚彦, 溝上 雅史
    肝臓 (一社)日本肝臓学会 55 (Suppl.1) A363 - A363 0451-4203 2014/04
  • 次世代シークエンサーを使用したC型慢性肝炎患者におけるIL28Bプロモーター領域の治療反応性に関与する新規遺伝子変異の同定
    竹田 努, 村田 一素, 杉山 真也, 青木 孝彦, 由雄 祥代, 西田 奈央, 山極 洋子, 是永 圭子, 是永 匡紹, 今村 雅俊, 考藤 達哉, 正木 尚彦, 渡辺 純夫, 溝上 雅史
    肝臓 (一社)日本肝臓学会 55 (Suppl.1) A436 - A436 0451-4203 2014/04
  • Nao Nishida, Hiromi Sawai, Koichi Kashiwase, Mutsuhiko Minami, Masaya Sugiyama, Wai-Kay Seto, Man-Fung Yuen, Nawarat Posuwan, Yong Poovorawan, Sang Hoon Ahn, Kwang-Hyub Han, Kentaro Matsuura, Yasuhito Tanaka, Masayuki Kurosaki, Yasuhiro Asahina, Namiki Izumi, Jong-Hon Kang, Shuhei Hige, Tatsuya Ide, Kazuhide Yamamoto, Isao Sakaida, Yoshikazu Murawaki, Yoshito Itoh, Akihiro Tamori, Etsuro Orito, Yoichi Hiasa, Masao Honda, Shuichi Kaneko, Eiji Mita, Kazuyuki Suzuki, Keisuke Hino, Eiji Tanaka, Satoshi Mochida, Masaaki Watanabe, Yuichiro Eguchi, Naohiko Masaki, Kazumoto Murata, Masaaki Korenaga, Yoriko Mawatari, Jun Ohashi, Minae Kawashima, Katsushi Tokunaga, Masashi Mizokami
    PLoS ONE 9 (2) e86449 - e86449 2014/02 [Refereed]
     
    Previous studies have revealed the association between SNPs located on human leukocyte antigen (HLA) class II genes, including HLA-DP and HLA-DQ, and chronic hepatitis B virus (HBV) infection, mainly in Asian populations. HLA-DP alleles or haplotypes associated with chronic HBV infection or disease progression have not been fully identified in Asian populations. We performed trans-ethnic association analyses of HLA-DPA1, HLA-DPB1 alleles and haplotypes with hepatitis B virus infection and disease progression among Asian populations comprising Japanese, Korean, Hong Kong, and Thai subjects. To assess the association between HLA-DP and chronic HBV infection and disease progression, we conducted high-resolution (4-digit) HLA-DPA1 and HLA-DPB1 genotyping in a total of 3,167 samples, including HBV patients, HBV-resolved individuals and healthy controls. Trans-ethnic association analyses among Asian populations identified a new risk allele HLA-DPB1*09 ∶ 01 (P = 1.36 × 10(-6); OR= 1.97; 95% CI, 1.50-2.59) and a new protective allele DPB1*02 ∶ 01 (P = 5.22 × 10(-6); OR = 0.68; 95% CI, 0.58-0.81) to chronic HBV infection, in addition to the previously reported alleles. Moreover, DPB1*02 ∶ 01 was also associated with a decreased risk of disease progression in chronic HBV patients among Asian populations (P = 1.55 × 10(-7); OR = 0.50; 95% CI, 0.39-0.65). Trans-ethnic association analyses identified Asian-specific associations of HLA-DP alleles and haplotypes with HBV infection or disease progression. The present findings will serve as a base for future functional studies of HLA-DP molecules in order to understand the pathogenesis of HBV infection and the development of hepatocellular carcinoma.
  • Kazumoto Murata, Masaya Sugiyama, Tatsuji Kimura, Sachiyo Yoshio, Tatsuya Kanto, Ikue Kirikae, Hiroaki Saito, Yoshihiko Aoki, Satoshi Hiramine, Teppei Matsui, Kiyoaki Ito, Masaaki Korenaga, Masatoshi Imamura, Naohiko Masaki, Masashi Mizokami
    Journal of Gastroenterology 49 (1) 126 - 137 0944-1174 2014/01 [Refereed]
  • Kiyoaki Ito, Hiroshi Yotsuyanagi, Hiroshi Yatsuhashi, Yoshiyasu Karino, Yasuhiro Takikawa, Takafumi Saito, Yasuji Arase, Fumio Imazeki, Masayuki Kurosaki, Takeji Umemura, Takafumi Ichida, Hidenori Toyoda, Masashi Yoneda, Eiji Mita, Kazuhide Yamamoto, Kojiro Michitaka, Tatsuji Maeshiro, Junko Tanuma, Yasuhito Tanaka, Masaya Sugiyama, Kazumoto Murata, Naohiko Masaki, Masashi Mizokami
    Hepatology 59 (1) 89 - 97 0270-9139 2014/01 [Refereed]
  • 黄疸が遷延した国内感染E型急性肝炎
    村田一素, 正木尚彦
    臨床消化器内科 28 1656 - 1661 2013/12 [Invited]
  • B型慢性肝炎診療up-to-date
    村田一素, 溝上雅史
    診断と治療 9 1271 - 1275 2013/12 [Invited]
  • 腹痛のない高齢者の肝胆道系酵素上昇
    村田一素, 正木尚彦
    臨床消化器内科 28 1191 - 1195 2013/12 [Invited]
  • Koichi Watashi, Guoxin Liang, Masashi Iwamoto, Hiroyuki Marusawa, Nanako Uchida, Takuji Daito, Kouichi Kitamura, Masamichi Muramatsu, Hirofumi Ohashi, Tomoko Kiyohara, Ryosuke Suzuki, Jisu Li, Shuping Tong, Yasuhito Tanaka, Kazumoto Murata, Hideki Aizaki, Takaji Wakita
    Journal of Biological Chemistry 288 (44) 31715 - 31727 0021-9258 2013/11 [Refereed]
  • 下血を契機に診断された肝原発腺扁平上皮癌大腸浸潤の一例
    竹田 努, 村田一素, 池田真美, 茶谷成, 小林正典, 青木孝彦, 松井哲平, 是永匡紹, 今村雅俊, 正木尚彦, 青木洋一郎, 尾上淑子, 矢田智之, 小飯塚仁彦, 青柳信嘉, 石田 剛, 渡辺純夫, 上村直実, 溝上雅史
    日本消化器病学会雑誌 110 1959 - 1967 2013/10 [Refereed]
  • 多施設共同研究における3剤併用療法のウイルス学的効果と副作用の検討
    山極 洋子, 正木 尚彦, 西田 奈央, 杉山 真也, 竹田 努, 青木 孝彦, 是永 匡紹, 村田 一素, 今村 雅俊, 溝上 雅史
    肝臓 (一社)日本肝臓学会 54 (Suppl.2) A556 - A556 0451-4203 2013/09
  • ポリメラーゼ阻害剤:C型肝炎治療2014: 経口抗ウイルス薬時代の到来
    村田一素
    肝胆膵 67 924 - 927 2013/09 [Invited]
  • Tsutomu Takeda, Kazumoto Murata, Naru Chatani, Yoichiro Aoki, Tomoyuki Yada, Yoshihiko Aoki, Hitohiko Koizuka, Masaaki Korenaga, Masatoshi Imamura, Tatsuya Kanto, Naohiko Masaki, Tsuyoshi Ishida, Sumio Watanabe, Masashi Mizokami, Naomi Uemura
    Clinical Journal of Gastroenterology 6 (4) 291 - 294 1865-7257 2013/08 [Refereed]
  • カプセル内視鏡にて経過観察が可能であった好酸球性腸炎の一例
    松井哲平, 村田一素, 金子正大, 尾上淑子, 小飯塚仁彦, 今村雅俊, 正木尚彦, 石田 剛, 溝上雅史
    日本消化器内視鏡学会雑誌 55 3394 - 3400 2013/06 [Refereed]
  • C型肝炎の自然予後-無治療住民検診における長期予後の検討-
    村田一素, 正木尚彦
    肝胆膵 66 417 - 422 2013/05 [Invited]
  • Sachiyo Yoshio, Tatsuya Kanto, Shoko Kuroda, Tokuhiro Matsubara, Koyo Higashitani, Naruyasu Kakita, Hisashi Ishida, Naoki Hiramatsu, Hiroaki Nagano, Masaya Sugiyama, Kazumoto Murata, Takasuke Fukuhara, Yoshiharu Matsuura, Norio Hayashi, Masashi Mizokami, Tetsuo Takehara
    Hepatology 57 (5) 1705 - 1715 0270-9139 2013/05 [Refereed]
     
    The polymorphisms in the interleukin (IL)-28B (interferon-lambda [IFN]-λ3) gene are strongly associated with the efficacy of hepatitis C virus (HCV) clearance. Dendritic cells (DCs) sense HCV and produce IFNs, thereby playing some cooperative roles with HCV-infected hepatocytes in the induction of interferon-stimulated genes (ISGs). Blood dendritic cell antigen 3 (BDCA3) DCs were discovered as a producer of IFN-λ upon Toll-like receptor 3 (TLR3) stimulation. We thus aimed to clarify the roles of BDCA3 DCs in anti-HCV innate immunity. Seventy healthy subjects and 20 patients with liver tumors were enrolled. BDCA3 DCs, in comparison with plasmacytoid DCs and myeloid DCs, were stimulated with TLR agonists, cell-cultured HCV (HCVcc), or Huh7.5.1 cells transfected with HCV/JFH-1. BDCA3 DCs were treated with anti-CD81 antibody, inhibitors of endosome acidification, TIR-domain-containing adapter-inducing interferon-β (TRIF)-specific inhibitor, or ultraviolet-irradiated HCVcc. The amounts of IL-29/IFN-λ1, IL-28A/IFN-λ2, and IL-28B were quantified by subtype-specific enzyme-linked immunosorbent assay (ELISA). The frequency of BDCA3 DCs in peripheral blood mononuclear cell (PBMC) was extremely low but higher in the liver. BDCA3 DCs recovered from PBMC or the liver released large amounts of IFN-λs, when stimulated with HCVcc or HCV-transfected Huh7.5.1. BDCA3 DCs were able to induce ISGs in the coexisting JFH-1-positive Huh7.5.1 cells. The treatments of BDCA3 DCs with anti-CD81 antibody, cloroquine, or bafilomycin A1 reduced HCVcc-induced IL-28B release, whereas BDCA3 DCs comparably produced IL-28B upon replication-defective HCVcc. The TRIF-specific inhibitor reduced IL-28B release from HCVcc-stimulated BDCA3 DCs. In response to HCVcc or JFH-1-Huh7.5.1, BDCA3 DCs in healthy subjects with IL-28B major (rs8099917, TT) released more IL-28B than those with IL-28B minor genotype (TG). Conclusion: Human BDCA3 DCs, having a tendency to accumulate in the liver, recognize HCV in a CD81-, endosome-, and TRIF-dependent manner and produce substantial amounts of IL-28B/IFN-λ3, the ability of which is superior in subjects with IL-28B major genotype. (HEPATOLOGY 2013) Copyright © 2012 American Association for the Study of Liver Diseases. + + + + + + + + + + + +
  • In vitroの系からみたPIVKA-IIと脈管侵襲
    村田一素
    肝胆膵 66 909 - 915 2013/04 [Invited]
  • ウイルス肝炎マーカーの選択と読み方
    村田一素, 正木尚彦
    Medical Practice 30 (2) 231 - 235 2013/02 [Invited]
  • 専門医に聞く-B型肝炎の治療-
    村田一素, 溝上雅史
    HIV感染症とAIDSの治療 4 58 - 62 2013/01 [Invited]
  • <総説>B型肝炎ウイルス感染における宿主免疫応答の重要性-特にNKT細胞の関与について-
    村田一素
    肝臓 54 (1) 7 - 18 2013/01 [Refereed]
  • Masaya Sugiyama, Tatsuji Kimura, Shigeko Naito, Motokazu Mukaide, Takanori Shinauchi, Masakatsu Ueno, Kiyoaki Ito, Kazumoto Murata, Masashi Mizokami
    Hepatology Research 42 (11) 1089 - 1099 1386-6346 2012/11 [Refereed]
  • Kiyoaki Ito, Atsushi Kuno, Yuzuru Ikehara, Masaya Sugiyama, Hiroaki Saito, Yoshihiko Aoki, Teppei Matsui, Masatoshi Imamura, Masaaki Korenaga, Kazumoto Murata, Naohiko Masaki, Yasuhito Tanaka, Shuhei Hige, Namiki Izumi, Masayuki Kurosaki, Shuhei Nishiguchi, Michiie Sakamoto, Masayoshi Kage, Hisashi Narimatsu, Masashi Mizokami
    Hepatology 56 (4) 1448 - 1456 0270-9139 2012/10 [Refereed]
  • C型肝炎治療の最前線 IL28B遺伝子多型による治療効果予測不一致に寄与する宿主因子の検討
    村田 一素, 杉山 真也, 溝上 雅史
    肝臓 (一社)日本肝臓学会 53 (Suppl.2) A575 - A575 0451-4203 2012/09
  • Sebastian Zeissig, Kazumoto Murata, Lindsay Sweet, Jean Publicover, Zongyi Hu, Arthur Kaser, Esther Bosse, Jahangir Iqbal, M Mahmood Hussain, Katharina Balschun, Christoph Röcken, Alexander Arlt, Rainer Günther, Jochen Hampe, Stefan Schreiber, Jody L Baron, D Branch Moody, T Jake Liang, Richard S Blumberg
    Nature Medicine 18 (7) 1060 - 1068 1078-8956 2012/07 [Refereed]
  • C型慢性肝炎における臨床背景の違いと治療法選択の現状と展開 C型慢性肝炎に対するペグインターフェロン・リバビリン併用療法における個別化医療 多施設共同前向き研究からの考察
    正木 尚彦, 杉山 真也, 田中 靖人, 伊藤 清顕, 村田 一素, 青木 孝彦, 斉藤 紘昭, 松井 哲平, 今村 雅俊, 溝上 雅史
    肝臓 (一社)日本肝臓学会 53 (Suppl.1) A45 - A45 0451-4203 2012/04
  • 最新の遺伝子研究からみた肝臓病の現状と個別化医療への展望 C型慢性肝炎と自然治癒に関連する第二遺伝要因の探索とその応用
    杉山 真也, 平峯 智, 西田 奈央, 伊藤 清顕, 村田 一素, 正木 尚彦, 宇都 浩文, 井戸 章雄, 坪内 博仁, 溝上 雅史
    肝臓 (一社)日本肝臓学会 53 (Suppl.1) A196 - A196 0451-4203 2012/04
  • C型肝炎基礎 Toll-like receptor 7 agonist刺激による末梢血リンパ球IFN-λ3誘導とその臨床的意義
    村田 一素, 杉山 真也, 溝上 雅史
    肝臓 (一社)日本肝臓学会 53 (Suppl.1) A340 - A340 0451-4203 2012/04
  • 甲状腺機能低下症における肝逸脱酵素の上昇
    村田一素, 正木尚彦
    臨床消化器内科 26 1675 - 1680 2011/12 [Invited]
  • Yasumi Furui, Yuji Hoshi, Kazumoto Murata, Kiyoaki Ito, Kou Suzuki, Shigeharu Uchida, Masahiro Satake, Masashi Mizokami, Kenji Tadokoro
    Journal of Medical Virology 83 (11) 1924 - 1929 0146-6615 2011/11 [Refereed]
  • Masaya Sugiyama, Ayano Inui, Tadasu Shin-I, Haruki Komatsu, Motokazu Mukaide, Naohiko Masaki, Kazumoto Murata, Kiyoaki Ito, Makoto Nakanishi, Tomoo Fujisawa, Masashi Mizokami
    Hepatology Research 41 (10) 936 - 945 1386-6346 2011/10
  • Hideto Suzuki, Kazumoto Murata, Takaya Gotoh, Masao Kusano, Hiroshi Okano, Takashi Oyamada, Yoshikazu Yasuda, Masatoshi Imamura, Masatoshi Kudo, Masashi Mizokami, Atsushi Sakamoto
    Journal of Gastroenterology 46 (10) 1219 - 1229 0944-1174 2011/10 [Refereed]
  • Universal B型ワクチンー日本におけるその必要性は?―.
    村田一素, 溝上雅史
    薬局 62 (8) 135 - 140 2011/08
  • ペグインターフェロン投与当日に虚血性大腸炎が出現したpersistently normal ALT (PNALT)の1例
    青木孝彦, 村田一素, 斎藤紘昭, 松井哲平, 伊藤清顕, 今村雅俊, 正木尚彦, 小林正典, 青木洋一郎, 尾上淑子, 西村 崇, 矢田智之, 吉澤 大, 小飯塚仁彦, 上村直実, 溝上雅史
    肝臓 52 765 - 769 2011/05 [Refereed]
  • C型慢性肝炎患者におけるIL28B関連SNPsに関する検討 どのSNPをどの測定法で検査すべきか
    伊藤 清顕, 正木 尚彦, 杉山 真也, 斉藤 紘昭, 青木 孝彦, 今村 雅俊, 村田 一素, 野村 秀幸, 髭 修平, 足立 浩司, 日野 啓輔, 八橋 弘, 折戸 悦朗, 田中 靖人, 溝上 雅史
    肝臓 (一社)日本肝臓学会 52 (Suppl.1) A216 - A216 0451-4203 2011/04
  • 遺伝子多型はHCV肝炎の病態、薬剤の効果にどう影響するのか
    村田一素, 伊藤清顕, 溝上雅史
    分子消化器病 8 29 - 34 2011/01 [Invited]
  • 急性肝障害の診断:急性肝障害時の生化学・血液検査, ウィルスマーカーの選択と解釈
    村田一素, 正木尚彦, 溝上雅史
    臨床消化器内科 25 1441 - 1445 2010/11 [Invited]
  • 肝胆膵薬物治療学の進歩―この30年―;強力ミノファ-ゲンシ-・グリチロン
    村田一素, 正木尚彦
    肝胆膵 61 (6) 1016 - 1023 2010/06 [Invited]
  • Kazumoto Murata, Hajime Kase, Hideyuki Kanemoto
    Internal Medicine 48 (17) 1559 - 1560 0918-2918 2009/10 [Refereed]
  • Hideto Suzuki, Kazumoto Murata, Atsushi Sakamoto
    Legal Medicine 11 (5) 237 - 240 1344-6223 2009/09 [Refereed]
  • Hypoxia-induced des-gamma-carboxy prothrombin production in hepatocellular carcinoma.
    Murata K, Suzuki H, Okano H, Oyamada T, Yasuda Y, Sakamoto A
    Int J Oncol 36 161 - 170 2009/07 [Refereed]
  • Impairment of clathrin-mediated endocytosis via cytoskeletal change by epithelial to fibroblastoid conversion in HepG2 cells: A possible mechanism of des-gamma-carboxy prothrombin production in hepatocellular carcinoma
    Murata K, Sakamoto A
    Int J Oncol 33 1149 - 1155 2008/10 [Refereed]
  • Norihiko Yamamoto, Kazumoto Murata, Kentaro Yoneda, Hiroyuki Fuke, Yumi Yamaguchi, Keiichi Ito, Kazushi Sugimoto, Katsuya Shiraki, Kei-Ichi Yamanaka, Hitoshi Mizutani, Yoshiyuki Takei
    International journal of molecular medicine 22 (1) 43 - 8 1107-3756 2008/07 
    Interleukin (IL)-18 plays an important role in the pathogenesis of several liver diseases as well as Fas-mediated apoptosis. However, the effects of IL-18 on Fas-mediated liver injury have not been well elucidated. Therefore, we examined the effects of IL-18 on Fas-mediated apoptosis in in vitro and in vivo experiments. We found that recombinant IL-18 protected mouse hepatocellular carcinoma cell lines, BNL5, from Fas-mediated apoptosis in a dose-dependent manner with up-regulation of both nuclear factor (NF) kappaB and X-linked inhibitors of apoptosis (XIAP). IL-18 transgenic (Tg) mice were also protected from Fas-mediated liver injury and this was further confirmed by histological study and TUNEL staining. In IL-18 Tg mice, up-regulation of XIAP and down-regulation of caspase 3 were observed after injection of anti-Fas, which was consistent with the in vitro findings. These results suggest that IL-18 suppresses Fas-mediated apoptosis of hepatocytes by up-regulation of NFkappaB and XIAP, following inhibition of caspase-3 activity. This observation raises the possibility that IL-18 could be a therapeutic strategy for Fas-mediated liver injury as a negative regulator of XIAP.
  • Splenectomy improves liver function in patients with liver cirrhosis
    Murata K, Ito K, Yoneda K, Shiraki K, Sakurai H, Ito M
    Hepato-Gastroenterology 55 1407 - 1411 2008/07 [Refereed]
  • Atsushi Sakamoto, Kazumoto Murata, Hideto Suzuki, Megumi Yatabe, Motoshi Kikuchi
    ACTA HISTOCHEMICA ET CYTOCHEMICA 41 (5) 143 - 147 0044-5991 2008 [Refereed]
  • Kentaro Yoneda, Kazumoto Murata, Kan Katayama, Eiji Ishikawa, Hiroyuki Fuke, Norihiko Yamamoto, Keiichi Ito, Katsuya Shiraki, Shinsuke Nomura
    American Journal of Kidney Diseases 50 (3) 455 - 462 0272-6386 2007/09 [Refereed]
  • Kazumoto Murata, Masami Moriyama
    Cancer Research 67 (7) 3263 - 3268 0008-5472 2007/04 [Refereed]
  • Kazumoto Murata, Minoru Hamada, Kazushi Sugimoto, Takeshi Nakano
    Journal of Hepatology 46 (2) 322 - 329 0168-8278 2007/02 [Refereed]
  • Kazumoto Murata, Hiroyuki Inoue, Yuji Kozuka
    Clinical Gastroenterology and Hepatology 5 (1) e3 - e3 1542-3565 2007/01 [Refereed]
  • Keiichi Ito, Katsuya Shiraki, Kiyomi Funatsuki, Hiroaki Ishiko, Kazushi Sugimoto, Kazumoto Murata, Takeshi Nakano, Michio Imawari
    Hepatology research : the official journal of the Japan Society of Hepatology 36 (4) 294 - 300 1386-6346 2006/12 
    Hepatitis C virus (HCV)-specific cytotoxic T lymphocytes (CTL) are thought to be effective in limiting viral spread and in clearing virus during infection. Therefore, we attempted to establish HCV-specific CTL and identify novel HCV-specific CTL epitopes in a patient with acute hepatitis C by a novel screening method using recombinant vaccinia viruses (rVV) and synthetic peptides. CD8(+)CD45RA(-) T cells (memory T cells) were isolated from peripheral blood mononuclear cells (PBMC) of a patient with acute hepatitis C. HCV-specific CTL were cloned at limited dilutions and tested for HCV-specific CTL activity using a standard (51)Cr release assay. CTL assay was performed using rVV expressing regions of HCV-J, and overlapping and truncated synthetic peptides from HCV-J. CTL recognizing the NS3 region were isolated by (51)Cr release assay with rVV-HCV. Isolated CTL were restricted by HLA class I molecules B(*)5603. We confirmed that isolated CTL recognized 8-mer amino acids in the NS3 region of HCV-J by (51)Cr release assay with overlapping and truncated synthetic peptides. In conclusion, we isolated HCV-specific CTL restricted by HLA-B(*)5603 and identified a novel HCV-specific CTL epitope (IPFYGKAI, amino acids 1373-1380) in the NS3 region. The identified HCV-specific CTL epitope might be useful for HCV therapy.
  • 脾摘術にて肝不全を離脱し得た非代償性肝硬変の2例
    伊藤圭一, 村田一素, 福家洋之, 井上知子, 山中 豊, 山本憲彦, 杉本和史, 白木克哉, 桜井洋至, 上本伸二, 中野 赳
    肝臓 47 30 - 37 2006/01 [Refereed]
  • Kazumoto Murata, Kazushi Sugimoto, Katsuya Shiraki, Takeshi Nakano
    World journal of gastroenterology 11 (43) 6848 - 52 1007-9327 2005/11 
    AIM: To determine the predictive factors for hepatocellular carcinoma (HCC) development in patients after spontaneous or therapeutic HBeAg seroconversion. METHODS: In 48 patients who seroconverted to anti-HBe positive during follow-up, the background factors for HCC development were analyzed. RESULTS: HCC was developed in six patients during follow-up (average follow-up after HBeAg seroconversion: 10.9+/-5.4 years). The incidence of HCC evaluated by Kaplan-Meier analysis was significantly higher in patients with abnormal aspartate aminotransferase (AST>40 IU/L) level, lower platelet counts (PLT< 10 x 10(4)/microL), lower albumin level (Alb<30 g/L), positive HBV-DNA or older age at seroconversion (>40 years). However, lower platelet count was the only predictive factor for HCC development shown by multivariate proportional-hazard analysis. CONCLUSION: Active hepatitis or advanced hepatitis at HBeAg seroconversion or progressive hepatitis even after HBeAg seroconversion would be the risk factors for HCC development. These predictive factors should be taken into account in determining the frequency of biochemical study or imaging studies for HCC surveillance.
  • Tomoko Inoue, Katsuya Shiraki, Hiroyuki Fuke, Yutaka Yamanaka, Kazumi Miyashita, Keiichi Ito, Masahiro Suzuki, Kazushi Sugimoto, Kazumoto Murata, Takeshi Nakano
    World journal of gastroenterology 11 (39) 6219 - 20 1007-9327 2005/10 
    Primary biliary cirrhosis (PBC) is an autoimmune disease characterized by anti-mitochondrial antibodies and destruction of intra-hepatic bile ducts. Though little is known about the etiology of PBC, some reports suggest that xenobiotics and viral infections may induce PBC. We describe a case of PBC after the aortoiliac reconstruction surgery using a Y-graft.
  • Macrocytic anemia during low-dose cisplatin and 5-fluorouracil through implanted infusion port for unresectable hepatobilliary malignancies
    Yamamoto N, Murata K, Fuke H, Inoue T, Yamanaka Y, Saitou Y, Ito K, Sugimoto K, Koyama M, Shiraki K, Nakano T
    Anticancer Res 25 1243 - 1246 2005/10 [Refereed]
  • N Yamamoto, E Ishikawa, K Murata
    Journal of Gastroenterology and Hepatology 20 (6) 952 - 952 0815-9319 2005/05 [Refereed]
  • Katsuya Shiraki, Takenari Yamanaka, Hidekazu Inoue, Tomoyuki Kawakita, Naoyuki Enokimura, Hiroshi Okano, Kazushi Sugimoto, Kazumoto Murata, Takeshi Nakano
    International journal of oncology 26 (5) 1273 - 81 1019-6439 2005/05 
    TNF-related apoptosis-inducing ligand (TRAIL), as well as Fas ligand, plays a pivotal role in lymphocyte cytotoxicity and the maintenance of immunological homeostasis in various tissues, but its physiological role in immune evasion of cancer cells remains unknown. We have previously shown strong resistance to TRAIL-induced cytotoxicity in human hepatocellular carcinomas (HCCs). The current study investigates the expression of TRAIL in HCCs. We found that three HCC cells, HepG2, Hep3B and Huh7 cells, constitutively express TRAIL mRNA and protein, as detected by reverse transcriptase PCR and Western blotting. Four of 10 human HCC tissues demonstrated positive staining for TRAIL, whereas non-tumor tissues showed little detectable staining. TRAIL expression on tumor cells was detected by flow cytometry and was dramatically induced after the addition of doxorubicin, a chemotherapeutic agent, or cytokine stimulation with TNF-alpha, IL-1beta or IL-18. This expression was induced principally via the NF-kappaB activation pathway, since IkappaB transfection significantly reduced TRAIL expression. In addition, the expressed TRAIL was functional. The TRAIL on HCC cells induced apoptosis in Jurkat cells that are sensitive to TRAIL-mediated apoptosis, and this process was specifically inhibited by recombinant TRAIL-receptors:Fc which binds to TRAIL. In conclusion, TRAIL expressed on the surface of HCC cells by cytokines or cytostatic drugs might contribute to an alternative mechanism that enables tumors to evade immune surveillance by inducing apoptosis of activated human lymphocytes.
  • 消化器癌の肝転移モデルの作製とその解析
    白木克哉, 村田一素
    分子消化器病 2 353 - 357 2005/04 [Invited]
  • Up-regulation of IL-18 by interferon alpha/ribavirin combination therapy induces an anti-viral effect in patients with chronic hepatitis C. Hepato-Gastroenterology 2005;52:547-551.
    Murata K, Yamamoto N, Kawakita T, Saito Y, Yamanaka Y, Sugimoto K, Shiraki K, Nakano T, Tameda Y
    Hepato-Gastroenterology 52 547 - 551 2005/04 [Refereed]
  • K Sugimoto, K Shiraki, Y Yamanaka, N Yamamoto, K Murata, T Nakano
    Journal of Gastroenterology and Hepatology 20 (4) 651 - 651 0815-9319 2005/04 [Refereed]
  • Tomoyuki Kawakita, Katsuya Shiraki, Yutaka Yamanaka, Yumi Yamaguchi, Yukiko Saitou, Naoyuki Enokimura, Norihiko Yamamoto, Hiroshi Okano, Kazushi Sugimoto, Kazumoto Murata, Takeshi Nakano
    International journal of oncology 26 (1) 87 - 93 1019-6439 2005/01 
    The TNF-like weak inducer of apoptosis (TWEAK) can induce diverse cellular responses, including cell death, inflammation, migration, and proliferation in various transformed cell lines. We investigated TWEAK sensitivity, TWEAK effects on nuclear factor-kappaB activation, and expression of TWEAK in the HT-29, LS180, SK-CO-1 and SW480 human colonic adenocarcinoma cell lines, all of which express the TWEAK receptor (Fn14). TWEAK alone induced cell death in SW480 cells and induced cell death of HT-29 cells after addition of IFN-gamma, actinomycin D or cycloheximide. TWEAK did not affect cell viability of LS-180 or SK-CO-1 cells. Activation of NF-kappaB was not obviously influenced by TWEAK in any of the cell lines. All four human colonic adenocarcinoma cell lines constitutively expressed TWEAK mRNA, protein and membrane-bound TWEAK antigen, as detected by RT-PCR, Western blotting and flow cytometry. Stimulation by an anticancer drug (camptothecin) augmented cell surface expression of TWEAK and all human colonic adenocarcinoma tissue samples studied (n=59) demonstrated positive staining for TWEAK antigen. Soluble TWEAK was detected in culture medium of these cell lines by ELISA and conditioned medium from SW480 cells incubated with anti-TWEAK antibody significantly inhibited endothelial cell tube formation in Matrigels. Thus, functional expression of TWEAK from human colonic adenocarcinoma cells may contribute to neovascularization.
  • Saitou Y, Shiraki K, Yamanaka Y, Yamaguchi Y, Kawakita T, Yamamoto N, Sugimoto K, Murata K, Nakano T
    World Journal of Gastroenterology 11 (4) 476 - 476 1007-9327 2005 [Refereed]
  • Inoue T, Shiraki K, Fuke H, , Yamanaka Y, Miyashita K, Ito K, Suzuki M, Sugimoto K, Murata K, Nakano T
    World Journal of Gastroenterology 11 (13) 2048 - 2048 1007-9327 2005 [Refereed]
  • Yamamoto N, Murata K, Nakano T
    World Journal of Gastroenterology 11 (47) 7545 - 7545 1007-9327 2005 [Refereed]
  • Okano H, Shiraki K, Yamanaka Y, Inoue H, Kawakita T, Saitou Y, Yamaguchi Y, Enokimura N, Ito K, Yamamoto N, Sugimoto K, Murata K, Nakano T
    World Journal of Gastroenterology 11 (30) 4650 - 4650 1007-9327 2005 [Refereed]
  • N YAMAMOTO, K SHIRAKI, Y YAMANAKA, K SUGIMOTO, K MURATA, T NAKANO
    Journal of Gastroenterology and Hepatology 19 (12) 1417 - 1417 0815-9319 2004/12 [Refereed]
  • Norihiko Yamamoto, Kazumoto Murata
    Gastroenterology 127 (5) 1290 - 1651 0016-5085 2004/11
  • Norihiko Yamamoto, Kazumoto Murata
    Gastroenterology 127 (5) 1290 - 1651 0016-5085 2004/11 [Refereed]
  • Yumi Yamaguchi, Katsuya Shiraki, Yutaka Yamanaka, Yukiko Saitou, Tomoyuki Kawakita, Hideaki Inoue, Naoyuki Enokimura, Norihiko Yamamoto, Hiroshi Okano, Kazushi Sugimoto, Kazumoto Murata, Takeshi Nakano
    Journal of Clinical Gastroenterology 38 (8) 723 - 724 0192-0790 2004/09 [Refereed]
  • Keiichi Ito, Katsuya Shiraki, Hiroshi Okano, Yukiko Saitou, Kazushi Sugimoto, Kazumoto Murata, Mutsumi Koyama, Takeshi Nakano
    Gastrointestinal Endoscopy 60 (2) 260 - 261 0016-5107 2004/08 [Refereed]
  • Tomoyuki Kawakita, Katsuya Shiraki, Yutaka Yamanaka, Yumi Yamaguchi, Yukiko Saitou, Naoyuki Enokimura, Norihiko Yamamoto, Hiroshi Okano, Kazushi Sugimoto, Kazumoto Murata, Takeshi Nakano
    Biochemical and Biophysical Research Communications 318 (3) 726 - 733 0006-291X 2004/06 [Refereed]
  • Adenoviral-mediated transfer of p53 gene enhances TRAIL-induced apoptosis in human hepatocellular carcinoma cells
    Inoue H, Shiraki K, Murata K, Sugimoto K, Kawakita T, Yamaguchi Y, Saitou Y, Enokimura N, Yamamoto N, Yamanaka Y, Nakano T
    Int J Mol Med 14 271 - 275 2004/03 [Refereed]
  • Expression of CD34-positive sinusoidal endothelial cells in patients with HBV-associated chronic liver disease
    Ohmori S, Shiraki K, Sugimoto K, Yamanaka Y, Yamaguchi Y, Saitou Y, Fujikawa K, Murata K, Nakano T
    Int J Mol Med 14 179 - 184 2004/02 [Refereed]
  • Yukiko Saitou, Katsuya Shiraki, Yumi Yamaguchi, Norihiko Yamamoto, Tomoyuki Kawakita, Hiroshi Okano, Kazushi Sugimoto, Kazumoto Murata, Takeshi Nakano
    Journal of Clinical Gastroenterology 38 (1) 89 - 90 0192-0790 2004/01 [Refereed]
  • Norihiko Yamamoto, Katsuya Shiraki, Yukiko Saitou, Tomoyuki Kawakita, Hiroshi Okano, Kazushi Sugimoto, Kazumoto Murata, Takeshi Nakano
    Journal of Clinical Gastroenterology 38 (1) 84 - 84 0192-0790 2004/01 [Refereed]
  • Hepatocellular carcinoma presenting with obstructive jaundice: A clinicopathological study of eight cases
    Murata K, Shiraki K, Kawakita T, Yamamoto N, Okano H, Takahisa S, Ohmori S, Masatoshi D, Atsuya S, Nakano T
    Hepato-Gastroenterology 50 2057 - 2060 2003/12 [Refereed]
  • Katsuya Shiraki, Kazushi Sugimoto, Yutaka Yamanaka, Yumi Yamaguchi, Yukiko Saitou, Keiichi Ito, Norihiko Yamamoto, Takenari Yamanaka, Katsuhiko Fujikawa, Kazumoto Murata, Takeshi Nakano
    International journal of molecular medicine 12 (5) 705 - 8 1107-3756 2003/11 
    The X-linked inhibitor of apoptosis (XIAP) is a member of a novel family of inhibitors of apoptosis. Since suppression of apoptosis is fundamentally important for carcinogenesis and tumor growth, we investigated the expression and function of XIAP in human hepatocellular carcinomas (HCCs). XIAP was expressed constitutively in HCC cell lines. Fourteen out of 20 (70%) HCC tissues demonstrated moderate or strong cytoplasmic staining for XIAP, whereas non-tumor parts showed negative or weak staining for XIAP by immunohistochemistry. In addition, XIAP expression was inversely correlated with apoptosis, but not with proliferation in HCC tissues. These results indicated that XIAP is a principal inhibitor of apoptosis overexpressed in human HCCs and that XIAP may be a potential target for gene therapy of human HCCs.
  • 感染性膵壊死に対する後腹膜アプロ-チによるネクロゼクトミ-
    伊佐治秀司, 中村育夫, 斉藤友希子, 村田一素, 上本伸二
    手術 57 1327 - 1334 2003/11 [Refereed]
  • Hiroshi Okano, Katsuya Shiraki, Hidekazu Inoue, Yutaka Yamanaka, Tomoyuki Kawakita, Yukiko Saitou, Yumi Yamaguchi, Naoyuki Enokimura, Norihiko Yamamoto, Kazushi Sugimoto, Kazumoto Murata, Takeshi Nakano
    Laboratory investigation; a journal of technical methods and pathology 83 (10) 1529 - 39 0023-6837 2003/10 
    The peroxisome proliferator-activated receptor-gamma (PPARgamma) high-affinity ligand, 15-deoxy-Delta-12,14-PGJ(2) (15d-PGJ(2)), is toxic to malignant cells through cell cycle arrest and apoptosis induction. In this study, we investigated the effects of 15d-PGJ(2) on apoptosis induction and expression of apoptosis-related proteins in hepatocellular carcinoma (HCC) cells. 15d-PGJ(2) induced apoptosis in SK-Hep1 and HepG2 cells at a 50 micro M concentration. Pretreatment with the pan-caspase inhibitor, benzyloxycarbonyl-Val-Ala-Asp (OMe) fluoromethyl ketone (2-VAD-fmk), only partially blocked apoptosis induced by 40 micro M 15d-PGJ(2). This indicated that 15d-PGJ(2) induction of apoptosis was associated with a caspase-3-independent pathway. 15d-PGJ(2) also induced down-regulation of the X chromosome-linked inhibitor of apoptosis (XIAP), Bclx, and apoptotic protease-activating factor-1 in SK-Hep1 cells but not in HepG2 cells. However, 15d-PGJ(2) sensitized both HCC cell lines to TNF-related apoptosis-induced ligand-induced apoptosis. In SK-Hep1 cells, cell toxicity, nuclear factor-kappaB (NF-kappaB) suppression, and XIAP down-regulation were induced by 15d-PGJ(2) treatment under conditions in which PPARgamma was down-regulated. These results suggest that the effect of 15d-PGJ(2) was through a PPARgamma-independent mechanism. Although cell toxicity was induced when PPARgamma was down-regulated in HepG2 cells, NF-kappaB suppression and XIAP down-regulation were not induced. In conclusion, 15d-PGJ(2) induces apoptosis of HCC cell lines via caspase-dependent and -independent pathways. In SK-Hep1 cells, the ability of 15d-PGJ(2) to induce cell toxicity, NF-kappaB suppression, or XIAP down-regulation seemed to occur via a PPARgamma-independent mechanism, but in HepG2 cells, NF-kappaB suppression by 15d-PGJ(2) was dependent on PPARgamma.
  • Long-term follow-up of patients with liver cirrhosis after endoscopic esophageal varices ligation therapy: comparison with endoscopic injection sclerotherapy
    Okano H, Shiraki K, Inoue H, Kawakita T, Deguchi M, Sugimoto K, Sakai T, Murata K, Nakano T
    Hepato-Gastroenterology 50 2013 - 2016 2003/10 [Refereed]
  • Fas stimulation activates NF-kappaB in SKHep-1 hepatocellular carcinoma cells
    Okano H, Shiraki K, Inoue H, Kawakita T, Saitou Y, Enokimura N, Yamamoto N, Sugimoto K, Murata K, Nakano T
    Oncol Rep 10 1145 - 1148 2003/08 [Refereed]
  • A new prognostic scoring system involving des-gamma-carboxyprothrombin as a useful marker for predicting prognosis in patients with hepatocellualar carcinoma
    Kawakita T, Shiraki K, Yamanaka Y, Yamaguchi Y, Saitou Y, Enokimura N, Yamamoto N, Okano H, Sugimoto K, Murata K, Yamakado K, Takeda K, Nakano T
    23 1115 - 1120 2003/08 [Refereed]
  • The PPARgamma ligand, 15-Deoxy-Delta12, 14-PGJ2, regulates apoptosis-related protein expression in cholangio cell carcinoma cells
    Okano H, Shiraki K, Inoue H, Kawakita T, Deguchi M, Sugimoto K, Sakai T, Murata K, Nakano T, Enjoji M
    Int J Mol Med 12 867 - 870 2003/08 [Refereed]
  • Hiroshi Okano, Katsuya Shiraki, Hidekazu Inoue, Tomoyuki Kawakita, Takenari Yamanaka, Masatoshi Deguchi, Kazushi Sugimoto, Takahisa Sakai, Shigeru Ohmori, Katsuhiko Fujikawa, Kazumoto Murata, Takeshi Nakano
    Laboratory Investigation 83 (7) 1033 - 1043 0023-6837 2003/07 [Refereed]
  • K. Murata, M. Lechmann, M. Qiao, T. Gunji, H. J. Alter, T. J. Liang
    Proceedings of the National Academy of Sciences 100 (11) 6753 - 6758 0027-8424 2003/05 [Refereed]
  • Hepatocellular carcinoma development in sustained viral responders to interferon therapy in patients with chronic hepatitis C
    Enokimura N, Shiraki K, Kawakita T, Saitou Y, Inoue H, Okano H, Yamamoto N, Deguchi M, Sakai T, Ohmori S, Fujikawa K, Murata K, Niki Y, Nakano T
    Anticancer Res 23 593 - 596 2003/05 [Refereed]
  • The usefulness of digital subtraction imaging with Levovist in the diagnosis of focal hepatic tumors
    Yamamoto K, Shiraki K, Nakanishi S, Deguchi M, Sugimoto K, Sakai T, Ohmori S, Murata K, Fuke H, Hashimoto A, Shimizu A, Okuda Y, Nakano T
    Int J Oncol 22 353 - 358 2003/03 [Refereed]
  • Qiao M, Murata K, Davis AR, Jeong SH, Liang TJ
    Hepatology 37 (1) 52 - 59 0270-9139 2003/01 [Refereed]
  • Over-expression of Smac promotes TRAIL-induced cell death in human hepatocellular carcinoma
    Okano H, Shiraki K, Inoue H, Kawakita T, Saitou Y, Enokimura N, Yamamoto N, Sugimoto K, Fujikawa K, Murata K, Nakano T
    Int J Mol Med 12 25 - 28 2003/01 [Refereed]
  • Takahisa Sakai, Katsuya Shiraki, Hidekazu Inoue, Hiroshi Okano, Masatoshi Deguchi, Kazushi Sugimoto, Shigeru Ohmori, Kazumoto Murata, Hiromichi Fujioka, Koujirou Takase, Yukihiko Tameda, Takeshi Nakano
    Journal of Medical Virology 68 (2) 175 - 181 0146-6615 2002/10 [Refereed]
  • Mono-arthritis following intensified interferon beta therapy for chronic hepatitis C
    Murata K, Shiraki K, Takase K, Nakano T, Tameda Y
    Hepatogastroenterology 49 1418 - 1419 2002/10 [Refereed]
  • The effect of endoscopic injection sclerotherapy on portal blood flow and liver function
    Sugimoto K, Shiraki K, Murata K, Ito T, Ohmori S, Sakai T, Yamanaka T, Takase K, Nakano T, Nakanishi S
    Hepatogastroenterology 49 1587 - 1590 2002/10 [Refereed]
  • Pneumothorax after diagnostic laparoscopy
    Shiraki K, Hamada M, Sugimoto K, Ito T, Murata K, Fujikawa K, Takase K, Nakano T, Tameda Y
    Hepatogastroenterology 49 1033 - 1035 2002/09 [Refereed]
  • Laparoscopic microwave coagulation therapy for small hepatocelluar carcinoma on the liver surface
    Okano H, Shiraki K, Inoue H, Kawakita T, Deguchi M, Sugimoto K, Sakai T, Ohmori S, Murata K, Nakano T
    Oncol Rep 9 1001 - 1004 2002/09 [Refereed]
  • Hidekazu Inoue, Katsuya Shiraki, Takenari Yamanaka, Shigeru Ohmori, Takahisa Sakai, Masatoshi Deguchi, Hiroshi Okano, Kazumoto Murata, Kazushi Sugimoto, Takeshi Nakano
    Laboratory Investigation 82 (9) 1111 - 1119 0023-6837 2002/09 [Refereed]
  • Masatoshi Deguchi, Katsuya Shiraki, Hidekazu Inoue, Hiroshi Okano, Takeshi Ito, Takenari Yamanaka, Kazushi Sugimoto, Takahisa Sakai, Shigeru Ohmori, Kazumoto Murata, Akihiro Furusaka, Hisashi Hisatomi, Takeshi Nakano
    Biochemical and Biophysical Research Communications 297 (1) 59 - 64 0006-291X 2002/09 [Refereed]
     
    Survivin functions to suppress cell death and regulate cell division, and is observed uniquely in tumor cells and developmental cells. However, the expression and regulation of survivin in non-transformed cells are not well elucidated. Therefore, we investigated the expression of survivin in a murine liver regeneration model after partial hepatectomy and intraperitoneal carbon tetrachloride (CCl(4)) injection. We found that the expression of survivin transcript and protein were markedly elevated with the onset of DNA synthesis and remained elevated during G2 and M phases during liver regeneration. In a normal mouse liver cell line, over-expression of survivin resulted in a decrease in the G0/G1 phase and an increase in the S and G2/M phases, resulting in Rb phosphorylation. These findings suggest that survivin is dramatically expressed in a cell cycle-dependent manner during liver regeneration and provide a new insight into the regulation of cell proliferation and differentiation.
  • Diagnosis of hepatocellular carcinoma using digital subtraction imaging with the contrast agent, Levovist: comparison with helical CT, digital subtraction angiography, and US angiography
    Yamamoto K, Shiraki K, Deguchi M, Sugimoto K, Sakai T, Ohmori S, Murata K, Hashimoto A, Shimizu A, Okuda Y, Nakano T
    9 789 - 792 2002/07 [Refereed]
  • Clinicopathological analysis of liver abscess in Japan
    Okano H, Shiraki K, Inoue H, Kawakita T, Yamamoto N, Deguchi M, Sugimoto K, Ohmori S, Murata K, Nakano T
    Int J Mol Med 10 627 - 630 2002/05 [Refereed]
  • Laparoscopic ethanol injection therapy for hepatocellular carcinoma
    Okano H, Shiraki K, Inoue H, Yamanaka T, Deguchi M, Sugimoto K, Sakai T, Ohmori S, Murata K, Nakano T
    Int J Oncol 20 267 - 271 2002/02 [Refereed]
  • Sequential fluctuation pattern of serum des-gamma-carboxy prothrombin levels detected by high-sensitive electrochemiluminescence system as an early predictive marker for hepatocellular carcinoma in patients with cirrhosis
    Shimizu A, Shiraki K, Ito T, Sugimoto K, Sakai T, Ohmori S, Murata K, Takase K, Tameda Y, Nakano T
    9 245 - 250 2002/02 [Refereed]
  • Efficacy of long-term interferon therapy in chronic hepatitis B patients with HBV genotype C
    Sakai T, Shiraki K, Inoue H, Okano H, Deguchi M, Sugimoto K, Ohmori S, Murata K, Nakano T
    10 201 - 204 2002/02 [Refereed]
  • Takahisa Sakai, Katsuya Shiraki, Hidekazu Inoue, Kazushi Sugimoto, Shigeru Ohmori, Kazumoto Murata, Koujiro Takase, Takeshi Nakano
    Digestive Diseases and Sciences 47 (2) 388 - 391 0163-2116 2002 [Refereed]
  • Okano H, Shiraki K, Inoue H, Yamanaka T, Deguchi M, Sugimoto K, Sakai T, Ohmori S, Fujikawa K, Murata K, Nakano T
    Anticancer Drugs 13 (1) 59 - 65 0959-4973 2002/01 [Refereed]
     
    Proliferator-activated receptor gamma (PPARgamma) is a nuclear receptor, which mainly associates with adipogenesis, but also appears to facilitate cell differentiation or apoptosis in certain malignant cells. This apoptosis induction by PPARgamma is increased by co-stimulation with tumor necrosis factor (TNF)-alpha-related apoptosis-inducing ligand (TRAIL), a member of the TNF family. In this study, we investigated the effect of PPARgamma on Fas-mediated apoptosis in hepatocellular carcinoma (HCC) cell lines. PPARgamma was expressed on all seven HCC cell lines and located in their nuclei. 15-Deoxy-Delta-12,14-prostaglandin J2 (15d- PGJ2), a PPARgamma ligand, inhibited cellular proliferation in HepG2, SK-Hep1 or HLE cells, unlike pioglitazone, another PPARgamma ligand, which did not have a significant influence on proliferation of these cells. However, 15d-PGJ2 facilitated Fas-mediated HCC apoptosis that could not be induced by Fas alone. These results suggest that PPARgamma can augment TNF-family-induced apoptosis.
  • Jujin Satoi, Kazumoto Murata, Martin Lechmann, Elanchezhiyan Manickan, Zhensheng Zhang, Heiner Wedemeyer, Barbara Rehermann, T. Jake Liang
    Journal of Virology 75 (24) 12121 - 12127 0022-538X 2001/12 [Refereed]
     
    ABSTRACT To study the effect of genetic immunization on transgenic expression of hepatitis C virus (HCV) proteins, we evaluated the immunological response of HCV transgenic mice to HCV expression plasmids. FVB/n transgenic mice expressing HCV structural proteins (core, E1, and E2) and wild-type (WT) FVB/n mice were immunized intramuscularly with plasmids expressing core (pHCVcore) or core/E1/E2 (pHCVSt). After immunization, HCV-specific humoral and cellular immune response was studied. Both WT and transgenic mice immunized with either HCV construct produced antibodies and exhibited T-cell proliferative responses against core or envelope. In WT mice immunized with pHCVSt, cytotoxic T-lymphocyte (CTL) activities were detected against E2 but not against core or E1, whereas strong CTL activities against core could be detected in WT mice immunized with pHCVcore. In pHCVSt-immunized, transgenic mice, CTL activities against the core or envelope were completely absent, but core-specific CTL activities could be detected in pHCVcore-immunized transgenic mice. A similar pattern of immune responses was also observed in other mouse strains, including a transgenic line expressing human HLA-A2.1 molecules (AAD mice). Despite the presence of a peripheral cellular immunity against HCV, no liver pathology or lymphocytic infiltrate was observed in these transgenic mice. Our study suggests a hierarchy of CTL response against the HCV structural proteins (E2 > core > E1) in vivo when the proteins are expressed as a polyprotein. The HCV transgenic mice can be induced by DNA immunization to generate anti-HCV antibodies and anticore CTLs. However, they are tolerant at the CTL level against the E2 protein despite DNA immunization.
  • Takahisa Sakai, Katsuya Shiraki, Kazushi Sugimoto, Shigeru Ohmori, Kazumoto Murata, Koujirou Takase, Takeshi Nakano, Yukihiko Tameda
    Journal of Hepatology 35 (6) 829 - 830 0168-8278 2001/12 [Refereed]
  • Comparison of screening methods for hepatocellular carcinomas in patients with cirrhosis
    Okano H, Shiraki K, Inoue H, Ito T, Yamanaka T, Deguchi M, Sugimoto K, Sakai T, Ohmori S, Murata K, Takase K, Nakano T
    21 2979 - 2982 2001/12 [Refereed]
  • Splenectomy enhances liver regeneration through tumor necrosis factor (TNF)-alpha following dimethylnitrosamine-induced cirrhotic rat model
    Murata K, Shiraki K, Sugimoto K, Takase K, Nakano T, Furusaka A, Tameda Y
    Hepatogastroenterology 48 1022 - 1027 2001/11 [Refereed]
  • Treatment of hepatocellular carcinoma and the exacerbation of liver function
    Okano H, Shiraki K, Inoue H, Deguchi M, Sugimoto K, Sakai T, Ohmori S, Murata K, Takase K, Nakano T
    Int J Oncol 19 1279 - 1282 2001/10 [Refereed]
  • Lechmann M, Murata K, Satoi J, Vergalla J, Baumert TF, Liang TJ
    Hepatology 34 (2) 417 - 423 0270-9139 2001/08 [Refereed]
  • Kazumoto Murata, Katsuya Shiraki
    Journal of Hepatology 35 (1) 147 - 147 0168-8278 2001/07 [Refereed]
  • Combining transcatheter arterial chemoembolization with percutaneous ethanol injection therapy for small size hepatocellular carcinoma
    Okano H, Shiraki K, Inoue H, Ito T, Yamanaka T, Deguchi M, Sugimoto K, Sakai T, Ohmori S, Murata K, Takase K, Nakano T
    Int J Oncol 19 909 - 912 2001/06 [Refereed]
  • Natural course of cavernous hepatic hemangioma
    Okano H, Shiraki K, Inoue H, Ito T, Yamanaka T, Deguchi M, Sugimoto K, Sakai T, Ohmori S, Murata K, Takase K, Nakano T
    8 411 - 414 2001/03 [Refereed]
  • “Variable echo sign” (ultrasonographical alteration of echogenicity) in cavernous hepatic hemangioma
    Okano H, Shiraki K, Inoue H, Ito T, Yamanaka T, Deguchi M, Sugimoto K, Sakai T, Ohmori S, Fujikawa K, Murata K, Takase K, Nakano T
    19 337 - 340 2001/03 [Refereed]
  • Low-dose chemotherapy of cisplatin and 5-fluorouracil or doxorubicin via implanted infusion port for unresectable hepatocellular carcinoma
    Murata K, Shiraki K, Kawakita T, Yamamoto N, Okano H, Nakamura M, Sakai T, Deguchi M, Ohmori S, Nakano T
    23 1719 - 1722 2000/09 [Refereed]
  • K. Murata, K. Shiraki, S. Kamei, K. Takase, T. Nakano
    Endoscopy 32 (7) 536 - 538 0013-726X 2000/07 [Refereed]
  • 門脈血栓を契機に肝性脳症を繰り返したB型肝硬変の1例
    黒田真紀子, 村田一素
    消化器病学会雑誌 96 1407 - 1411 1999/12 [Refereed]
  • カナマイシン投与によりBTRの上昇とともに不定愁訴が著明改善した肝内門脈静脈短絡の一例
    村田一素, 黒田真紀子
    現代医療 31 150 - 151 1999/02 [Refereed]
  • Disappearance of gastric antral vascular ectasia after percutaneous transhepatic obliteration.
    Murata K, Yoshimura H, Uemura S, Sugimoto K, Takase K, Nakano T
    Hepatogastroenterology 46 185 - 188 1999/01
  • Long-term effect of prophylactic endoscopic injection sclerotherapy on liver function
    Murata K, Sugimoto K, Okuda K, Shimizu A, Takase K, Nakano T, Tameda
    Hepatogastroenterology 45 1726 - 1730 1998/11 [Refereed]
  • 臨床検査の見方
    石原明徳, 村田一素
    Medical Technology 26 84 - 88 1998/01 [Invited]
  • Liver cirrhosis with synchronous gas gangrene and spontaneous bacterial peritonitis due to E. coli
    Murata K, Shimizu A, Takase K, Nakano T, Tameda Y
    J Gastroenterol 32 264 - 267 1997/03 [Refereed]
  • A case of lipoma of the terminal ileum treated by endoscopic removal
    Yoshimura H, Murata K, Takase K, Nakano T, Tameda Y
    Gastrointest Endosc 46 461 - 463 1997/03 [Refereed]
  • Asymptomatic primary pulmonary hypertension associated with liver cirrhosis
    Murata K, Shimizu A, Takase K, Nakano T, Tameda Y
    J Gastroenterol 32 102 - 104 1997/01 [Refereed]
  • Long term follow-up for patients with liver cirrhosis after partial splenic embolization
    Murata K, Shiraki K, Takase K, Nakano T, Tameda Y
    Hepatogastroenterology 43 1212 - 1217 1996/12 [Refereed]
  • A case of hemobilia after percutaneous liver biopsy treated by transcatheter arterial embolization with Histoacryl
    Murata K, Oohashi Y, Takase K, Nakano T, Tameda Y
    Am JGastroenterol 91 160 - 160 1996/01 [Refereed]
  • Association of prurigo with hepatitis C virus infection
    Kanazawa K, Yaoita H, Tsuda F, Murata K, Okamoto H
    131 852 - 853 1995/08 [Refereed]
  • 非A非B肝炎多発地域における血清疫学的調査
    村田一素, 国吉幹夫, 白木克哉, 浜田 実, 中野 赳, 津田文男
    肝臓 36 458 - 462 1995/05 [Refereed]
  • Abdominal Ultrasonographic screening of schoolchildren -with special reference to the frequency of the fatty liver
    Shiraki K, Sugimoto N, Murata K, Koyama M, Takase K, Nakano T, Tameda Y
    Mie Medical Journal 45 113 - 117 1995/02 [Refereed]
  • Pairoj Luengrojanakul, Kriengsak Vareesangthip, Termchai Chainuvati, Kazumoto Murata, Fumio Tsuda, Hajime Tokita, Hiroaki Okamoto, Yuzo Miyakawa, Makoto Mayumi
    Journal of Medical Virology 44 (3) 287 - 292 0146-6615 1994/11 [Refereed]
  • K. Masuko, K. Okuda, T. Meguro, N. Murayama, T. Mitsui, T. Ohmori, K. Murata, F. Tsuda, H. Okamoto
    Journal of Viral Hepatitis 1 (1) 65 - 71 1352-0504 1994/09 [Refereed]
  • SUSUMU NAKATA, PHAM SONG, DAO DINH DUC, NGUYEN XUAN QUANG, KAZUMOTO MURATA, FUMIO TSUDA, HIROAKI OKAMOTO
    Journal of Gastroenterology and Hepatology 9 (4) 416 - 419 0815-9319 1994/08 [Refereed]
  • 膵嚢胞の出現を認めたLemmel症候群の1例. 胆と膵 1994;15:343-347.
    村田一素, 我山秀孝, 国吉幹夫, 為田靭彦, 小坂義種, 中野 赳
    胆と膵 15 343 - 347 1994/03 [Refereed]
  • 肝硬変、特発性細菌性腹膜炎を併発したアルコ-ル性慢性膵炎の1例
    村田一素, 我山秀孝, 藤川勝彦, 国吉幹夫, 為田靭彦, 小坂義種, 中野 赳
    三重医学 38 187 - 190 1994 [Refereed]
  • Markers of hepatitis C and B virus infections among blood donors in Ho Chi Minh City and Hanoi, Vietnam
    Song P, Duc DD, Hien B, Nakata S, Chosa T, Watanabe J, Tsuda F, Murata K, Okamoto H
    Clin Diagn Lab Immunol 1 413 - 418 1994/01 [Refereed]
  • 大腿動脈塞栓症に腎梗塞を併発し、ネフロ-ゼ症候群をきたした1例
    村田一素, 我山秀孝, 藤川勝彦, 国吉幹夫
    三重医学 37 401 - 404 1993/04 [Refereed]
  • 肺気腫・慢性気管支炎患者に対する臭化オキシトロピウム(テルシガンエロゾル)の有用性の検討
    国吉幹夫, 清水敦哉, 村田一素, 我山秀孝
    The Therapeutic Research 14 253 - 258 1993/03 [Refereed]
  • 腹部CTにてwhirl signを認め術前診断しえた続発性小腸捻転の1例1993;54:145-148.
    竹内謙二, 我山秀孝, 村田一素
    日本臨床外科医学雑誌 54 145 - 148 1993/02 [Refereed]
  • 腹部超音波検査にて経時的観察し得た胆道回虫迷入症の1例
    村田一素, 我山秀孝, 清水敦哉, 竹内謙二, 国吉幹夫, 為田靭彦, 小坂義種, 中野 赳
    超音波医学 20 25 - 29 1993/01 [Refereed]
  • 多発性尿管憩室の2例. 臨床泌尿器科 1992;46:764-766
    村田一素, 森下文夫, 森 幸夫
    46 764 - 766 1992/09 [Refereed]
  • 腹腔鏡にて虫卵を観察し得た日本住血吸虫症の2例
    村田一素, 松本久史, 渡辺一美, 山田昌信, 高瀬幸次郎, 中野 赳, 為田靭彦, 小坂義種, 腹腔鏡にて虫卵を観察し得た日本住血吸虫症, 三重医学
    三重医学 36 455 - 460 1992/05 [Refereed]
  • 胸腔内伏針の一症例. 三重医学
    村田一素, 清水敦哉, 浜田 実, 国吉幹夫, 小西得司, 中野 赳
    三重医学 36 261 - 264 1992/03 [Refereed]
  • 虚血性大腸炎を合併した混合性結合組織病の一例
    浜田 実, 村田一素, 清水敦哉, 白木克哉, 国吉幹夫
    35 363 - 366 1991/04 [Refereed]
  • 特発性心室性頻拍の2例
    村田一素, 上野富生, 山室匡史, 増田岳一, 東 良久, 松本久司, 渡辺一美
    三重医学 35 373 - 376 1991/03 [Refereed]
  • 拡張型心筋症様病態を呈した甲状腺機能亢進症の一例
    浜田 実, 村田一素, 清水敦哉, 白木克哉, 国吉幹夫, 桝屋正浩, 安田正樹, 伊藤信康, 田川新生, 村田佐門, 玉置久雄
    三重医学 35 347 - 351 1991/03 [Refereed]


Copyright © MEDIA FUSION Co.,Ltd. All rights reserved.